CAHIC(SH:600195)2025-04-11 14:10Financial Performance - The company's operating revenue for 2024 reached CNY 6,017,190,375.67, an increase of 11.30% compared to CNY 5,406,312,590.46 in 2023[21] - The net profit attributable to shareholders of the listed company was CNY 70,884,445.64, a decrease of 82.41% from CNY 403,051,611.99 in the previous year[21] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 62,137,902.01, down 77.72% from CNY 278,858,364.79 in 2023[21] - The net cash flow from operating activities was CNY 419,565,593.23, an increase of 12.65% compared to CNY 372,461,428.84 in 2023[21] - Basic earnings per share decreased by 82.42% to CNY 0.0694 compared to CNY 0.3947 in 2023[22] - Net profit attributable to shareholders decreased by 82.41% due to a decline in gross profit and investment income[22] - The weighted average return on equity decreased by 6.17 percentage points to 1.29% from 7.46% in 2023[22] Assets and Liabilities - The total assets at the end of 2024 were CNY 8,843,999,066.31, a decrease of 1.14% from CNY 8,946,377,928.42 at the end of 2023[21] - The net assets attributable to shareholders of the listed company were CNY 5,505,042,539.52, a slight decrease of 0.28% from CNY 5,520,675,866.70 at the end of 2023[21] - The company reported a net cash outflow from financing activities of ¥496,179,946.71, a significant decrease of 165.34% compared to the previous year, primarily due to increased cash used for debt repayment[46] - The accounts payable increased by 291.84% to ¥255,443,942.00, indicating a rise in external payment obligations[59] Dividends and Shareholder Returns - The company plans to distribute a cash dividend of CNY 0.23 per 10 shares, totaling CNY 23,486,409.98, based on a total share capital of 1,021,148,260 shares[6] - The cash dividend distribution for the year 2023 is set at 0.119 yuan per share, totaling approximately 121.52 million yuan, which represents about 30.15% of the net profit attributable to shareholders[146] - The cumulative cash dividend amount over the last three accounting years is approximately 328.81 million yuan, with a cash dividend ratio of 96.33% based on the average annual net profit[151] Research and Development - The company is committed to high-quality development and innovation as part of its strategic goals for the "14th Five-Year Plan" period[32] - R&D expenses increased by 17.13% to ¥143,898,523.68, primarily due to higher direct material and testing costs associated with R&D projects[46] - Total R&D investment amounted to ¥159,306,758.78, representing 2.65% of operating revenue[54] - The number of R&D personnel is 468, accounting for 11% of the total workforce[55] - The company is actively involved in the research and development of various vaccines, including a rabies inactivated vaccine and a vaccine for pseudorabies in pigs[71] Market and Product Development - The company achieved a significant market share in key products such as foot-and-mouth disease vaccine and ST pig fever vaccine, with a focus on large clients and major products[32] - The company is actively expanding its product offerings in the pet market, integrating various marketing strategies and accelerating product development[34] - The company is expanding its product offerings in pet nutrition and health products[73] - The company plans to expand its international market presence as part of its "Belt and Road" initiative, enhancing competitiveness[100] Corporate Governance and Compliance - The company emphasizes that forward-looking statements in the report do not constitute substantive commitments to investors, highlighting potential investment risks[7] - The company has received a standard unqualified audit report from Tianjian Accounting Firm[5] - The company is committed to enhancing corporate governance and compliance with legal regulations, ensuring no insider trading incidents occurred during the reporting period[112] - The company’s audit committee emphasized the importance of independent and objective auditing practices, contributing to improved corporate governance and internal control[131] Environmental and Social Responsibility - The company invested approximately ¥29.83 million in environmental protection during the reporting period[157] - The company has implemented comprehensive pollution prevention measures, ensuring that all wastewater and waste gas meet discharge standards[160] - Total investment in poverty alleviation and rural revitalization projects amounted to 1.32 million CNY, with 1.1 million CNY allocated for targeted assistance in Xiaoxian County[175] - The company donated a total of 150,000 CNY to charity initiatives, including 100,000 CNY for the "Charity One Day Donation" event in Linyi City[174] Strategic Planning and Future Outlook - The company aims to enhance its position as a leader in the animal health and feed additive industry, focusing on green development and innovation[99] - The company plans to balance traditional industry upgrades with the development of strategic emerging industries to enhance competitiveness and resilience in the supply chain[105] - The company will strengthen risk prevention measures to ensure safety in development and maintain national security responsibilities[107] - The company provided a positive outlook for the next quarter, projecting a revenue increase of 25% to 1.875 billion RMB[119]